A multicenter phase II study of low-dose erlotinib in frail patients with EGFR mutation-positive, non-small cell lung cancer: Thoracic oncology research group (TORG) trial 1425.

被引：2
|
作者：
Yamada, Kazuhiko
Miyamoto, Shingo
Azuma, Koichi
Ishii, Hidenobu
Bessho, Akihiro
Fukamatsu, Nobuaki
Kunitoh, Hideo
Ishii, Mari
Tanaka, Hiroshi
Aono, Hiromi
Nakahara, Yoshiro
Kusaka, Kei
Hosomi, Yukio
Kikuchi, Norihiro
Mori, Yoshiaki
Itani, Hidetoshi
Kasai, Takashi
Ichiki, Masao
Seki, Nobuhiko
Okamoto, Hiroaki
机构：
[1] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan
[2] Japanese Red Cross Med Ctr, Tokyo, Japan
[3] Japanese Red Cross Okayama Hosp, Okayama, Japan
[4] Yokohama Municipal Citizens Hosp, Yokohama, Kanagawa, Japan
[5] Niigata Canc Ctr Hosp, Dept Resp Med, Niigata, Japan
[6] Mitsui Mem Hosp, Tokyo, Japan
[7] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[8] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan
[9] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[10] Kasumigaura Med Ctr, Tsuchiura, Ibaraki, Japan
[11] Iwate Cent Prefectural Hosp, Morioka, Iwate, Japan
[12] Japanese Red Cross Ise Hosp, Ise, Japan
[13] Tochigi Canc Ctr, Dept Resp Med, Utsunomiya, Tochigi, Japan
[14] Kyushu Med Ctr, Fukuoka, Fukuoka, Japan
[15] Teikyo Univ, Sch Med, Tokyo, Japan
[16] Yokohama Municipal Citizens Hosp, Dept Resp Med & Med Oncol, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9063
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
    Tanaka, Satomi
    Uchino, Junji
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S369 - S372
  • [22] A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
    Mamesaya, Nobuaki
    Fukui, Tomoya
    Takahashi, Toshiaki
    Kishi, Kazuma
    Yoshizawa, Takahiro
    Tokito, Takaaki
    Azuma, Koichi
    Morikawa, Kei
    Okuma, Yusuke
    Yoshioka, Hiroshige
    Hosokawa, Shinobu
    Kasai, Takashi
    Masubuchi, Ken
    Nakamichi, Shinji
    Aga, Masaharu
    Sasaki, Jiichiro
    Igawa, Satoshi
    Kada, Akiko
    Naoki, Katsuhiko
    Okamoto, Hiroaki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
    Meinrenken, Susanne
    PNEUMOLOGIE, 2018, 72 (04): : 246 - 246
  • [24] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
  • [25] A PHASE II STUDY OF ERLOTINIB IN JAPANESE EGFR MUTATION POSITIVE PATIENTS WITH PRETREATED NON-SMALL CELL LUNG CANCER (NSCLC):LUNG ONCOLOGY GROUP IN KYUSHU, JAPAN (LOGIK0803)
    Yamada, Kazuhiko
    Kawakami, Satoru
    Saruwatari, Kouichi
    Morinaga, Ryotaro
    Izumi, Miiru
    Aragane, Naoko
    Nagata, Shuya
    Kishimoto, Junji
    Takayama, Koichi
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1261 - S1262
  • [26] EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib
    Winther-Larsen, Anne
    Ebert, Eva Boysen Fynboe
    Meldgaard, Peter
    Sorensen, Boe Sandahl
    CLINICAL LUNG CANCER, 2019, 20 (03) : 161 - +
  • [27] Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin
    Okamoto, Kunio
    Okamoto, Isamu
    Hatashita, Erina
    Kuwata, Kiyoko
    Yamaguchi, Haruka
    Kita, Aya
    Yamanaka, Kentaro
    Ono, Mayumi
    Nakagawa, Kazuhiko
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (01) : 204 - 213
  • [28] A PHASE I/II STUDY OF COMBINATION CHEMOTHERAPY WITH ERLOTINIB AND S-1 IN PRETREATED NON-SMALL CELL LUNG CANCER (NSCLC): THORACIC ONCOLOGY RESEARCH GROUP (TORG) 0808/0913
    Nogami, Naoyuki
    Kozuki, Toshiyuki
    Hida, Naoya
    Hosomi, Yukio
    Seki, Nobuhiko
    Okamoto, Hiroaki
    Eguchi, Kenji
    Shibuya, Masahiko
    Morita, Satoshi
    Shinkai, Tetsu
    Watanabe, Koshiro
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1163 - S1163
  • [29] A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
    Yasuda, Hiroyuki
    Ichihara, Eiki
    Sakakibara-Konishi, Jun
    Zenke, Yoshitaka
    Takeuchi, Shinji
    Morise, Masahiro
    Hotta, Katsuyuki
    Sato, Mineyoshi
    Matsumoto, Shingo
    Tanimoto, Azusa
    Matsuzawa, Reiko
    Kiura, Katuyuki
    Takashima, Yuta
    Yano, Seiji
    Koyama, Junji
    Fukushima, Takahiro
    Hamamoto, Junko
    Terai, Hideki
    Ikemura, Shinnosuke
    Takemura, Ryo
    Goto, Koichi
    Soejima, Kenzo
    LUNG CANCER, 2021, 162 : 140 - 146
  • [30] A phase II trial of induction Erlotinib followed by chemotherapy with Platinum plus Pemetrexed ± Bevacizumab for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
    Tani, Tetsuo
    Soejima, Kenzo
    Naoki, Katsuhiko
    Arai, Daisuke
    Ishioka, Kouta
    Ohgino, Keiko
    Nishino, Makoto
    Kuroda, Aoi
    Yasuda, Hiroyuki
    Betsuyaku, Tomoko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345